Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 4Carcinoma, Renal Cell 4Recurrence 1Prostatic Hyperplasia 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Kidney Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1

Interventions

Dutasteride 5acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2Transurethral Resection of Prostate 2Therapeutics 2Radiotherapy 2Prostatectomy 2Blood Specimen Collection 2proxalutamide 1polyphenon E 1mirabegron 1Urination 1TroVax 1Transurethral Resection of Bladder 1Tamsulosin 1Standard of Care 1Risedronic Acid 1Psychiatric Rehabilitation 1Prostate-Specific Antigen 1Papaverine 1Oxygen 1Nitrous Oxide 1Needles 1Microspheres 1Magnetic Resonance Spectroscopy 1Lycopene 1Levofloxacin 1Finasteride 1Electroacupuncture 1Doxazosin 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Hyperplasia × TroVax × Clear all
NCT01194960 2020-10-19

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

Oxford BioMedica

Phase 2 Terminated
25 enrolled
Genitourinary

Prostatic Hyperplasia, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡